TruScreen Group (TRU) Investor presentation summary

Business overview and product

• AI-enabled real-time cervical cancer screening device with two manufacturing bases: China (for local market) and Australia (for other markets), supporting preferential access and global reach.

• Recurring revenue model through mandatory Single Use Sensor (SUS) for each patient screened.

• Over 1 million women screened, 1,000+ devices operational, and regulatory approvals in 14 countries.

• Recognized by WHO, UNITAID, and included in major clinical guidelines in China.

• Strategic alliance with Dalton Bio to distribute HPV DNA tests, expanding product portfolio and market reach.

Financial performance

• FY25 sales of NZ$1.7m, down from NZ$2.1m in FY24, mainly due to program delays in Zimbabwe, Vietnam, Indonesia, and Uzbekistan.

• FY26 sales forecast to exceed NZ$2.8m, with expected monthly cash flow positivity by March 2026.

• FY25 revenue breakdown: China 88%, Mexico 7%, Vietnam 2%, others 3%.

• FY26 projected revenue diversification: China 63%, Vietnam 11%, India/Indonesia 7%, Dalton Bio HPV 7%, others.

• Net assets at NZ$1.0m and cash at NZ$0.4m at FY25 year-end.

Market expansion and strategy

• China remains the largest market, accounting for over 85% of global sales in FY25, with expansion into six key provinces and increased SUS usage per device.

• Vietnam launched a 5-year, 260,000-women screening program in Ho Chi Minh City, expected to become the second largest market in FY26.

• India re-entry with new distributor, first sales completed, and Dalton Bio HPV products to be distributed.

• Indonesia and Uzbekistan achieved product registration and commenced commercial activities.

• Public screening programs in Zimbabwe, Uzbekistan, and Eswatini to drive growth in Africa.